A newly developed male contraceptive, styrene maleic anhydride (SMA), was injected in the vas deferens of male rhesus monkeys for safety evaluation at the dose of 100 mg (contraceptive dose, CD), 250 mg (CD x 2.5) and 500 mg (CD x 5.0), and the monkeys were kept under observation for one year. The observed behavioural, haematological, biochemical and histopathological parameters in treated monkeys were comparable to controls. The results suggest the polymer SMA to be safe up to 5 times CD in monkeys.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/0010-7824(90)90021-m | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!